ML414(NGI-1)
- Product Name
- ML414(NGI-1)
- CAS No.
- 790702-57-7
- Chemical Name
- ML414(NGI-1)
- Synonyms
- NGI-1;ML414;NGI1 NEW;ML414(NGI-1);NGI-1 (ML414);NGI-1 >=95% (HPLC);ML-414;ML414;NGI 1;NGI-1; NGI1; NGI 1; ML414; ML 414; ML-414、;ML 414,inhibit,Inhibitor,NGI 1,ML-414,NGI-1,Virus Protease,NGI1;5-(N,N-Dimethylsulfamoyl)-N-(5-methylthiazol-2-yl)-2-(pyrrolidin-1-yl)benzamide
- CBNumber
- CB94664139
- Molecular Formula
- C17H22N4O3S2
- Formula Weight
- 394.51
- MOL File
- 790702-57-7.mol
ML414(NGI-1) Property
- Density
- 1.372±0.06 g/cm3(Predicted)
- storage temp.
- 2-8°C
- solubility
- Soluble in DMSO (up to 5 mg/ml)
- form
- powder
- pka
- 7.48±0.50(Predicted)
- color
- white to beige
- Stability:
- Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- SML1620
- Product name
- NGI-1
- Purity
- ≥95% (HPLC)
- Packaging
- 5mg
- Price
- $108
- Updated
- 2024/03/01
- Product number
- SML1620
- Product name
- NGI-1
- Purity
- ≥95% (HPLC)
- Packaging
- 25mg
- Price
- $261
- Updated
- 2024/03/01
- Product number
- 6652
- Product name
- NGI1
- Purity
- ≥98%(HPLC)
- Packaging
- 25
- Price
- $181
- Updated
- 2021/12/16
- Product number
- 6652
- Product name
- NGI1
- Purity
- ≥98%(HPLC)
- Packaging
- 5
- Price
- $78
- Updated
- 2021/12/16
- Product number
- D477148
- Product name
- 5-(Dimethylsulfamoyl)-N-(5-methyl-1,3-thiazol-2-yl)-2-(pyrrolidin-1-yl)benzamide
- Packaging
- 5mg
- Price
- $130
- Updated
- 2021/12/16
ML414(NGI-1) Chemical Properties,Usage,Production
Description
NGI-1 (790702-57-7) is a cell-permeable inhibitor of oligosaccharyltransferase (OST) – IC50 = 1.1 μM.1 It blocks cell-surface localization and signaling of the epidermal growth factor receptor (EGFR) glycoprotein and selectively arrests proliferation only in cells dependent on EGFR for survival. NGI-1 caused G1 arrest and senescence in RTK-dependent NSCLC cells (PC9, HCC827, H3255,H1581). NGI-1 displays antiviral behavior against various flaviviruses (Dengue, West Nile, Yellow fever and Zika).2 It also was able to overcome resistance to EGFR tyrosine kinase inhibitors in mutant NSCLC cells3 and enhance radiosensitivity and cytotoxic effects of chemotherapy in glioma cells with high levels of RTK activation4.
storage
Store at +4°C
References
1) Lopez-Sambrooks et al. (2016), Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells; Nature Chem. Biol. 12 1023 2) Puschnik et al. (2017), A small molecule oligosaccharyltransferase inhibitor with pan-flaviviral activity; Cell Rep. 21 3032 3) Lopez-Sambrooks et al. (2018), Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors; Cancer Res. July 19, 2018 Epub ahead of print 4) Baro et al. (2018), Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity; Clin. Cancer Res. July 2, 2018 Epub ahead of print